-+ 0.00%
-+ 0.00%
-+ 0.00%
Shiyao Group announced that for the nine months ended September 30, 2026, the Group's total revenue was 25.26 billion yuan, up 27.0% year on year; the Company's shareholders should account for reported profit of 7.076 billion yuan, up 101.5% year on year; basic profit of 7.22 billion yuan, up 134.5% year on year. Revenue from the proprietary pharmaceutical business was RMB 21.648 billion, up 40.1% year on year, of which license fee revenue was 6.268 billion yuan, up 307.0% year on year; revenue from raw material products was RMB 2,336 billion, down 22.3% year on year; and revenue from functional foods and other products was RMB 1,276 billion, down 11.1% year on year.
Share
Listen to the news
Shiyao Group announced that for the nine months ended September 30, 2026, the Group's total revenue was 25.26 billion yuan, up 27.0% year on year; the Company's shareholders should account for reported profit of 7.076 billion yuan, up 101.5% year on year; basic profit of 7.22 billion yuan, up 134.5% year on year. Revenue from the proprietary pharmaceutical business was RMB 21.648 billion, up 40.1% year on year, of which license fee revenue was 6.268 billion yuan, up 307.0% year on year; revenue from raw material products was RMB 2,336 billion, down 22.3% year on year; and revenue from functional foods and other products was RMB 1,276 billion, down 11.1% year on year.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending